On September 6, 2016, the US Preventive Services Task Force (USPSTF) issued final recommendations on Screening for Latent Tuberculosis Infection (LTBI). As anticipated, the USPSTF recommended screening of asymptomatic adults (18 years of age and older) for LTBI. The final recommendation, associated articles published in JAMA and a variety of related resources (including one for consumers) are available at the following URL:
NTCA and Stop TB USA issued a press release about the “B” recommendation citing, ”The new USPSTF “B” recommendation for LTBI screening is a major step forward in support of expanded TB testing for people at highest risk. By combining screening with treatment of those infected, active TB could be prevented in the majority of people getting sick with the disease today. The USPSTF recommendations provide an historic opportunity to reduce dramatically the number of people in the U.S. who develop active TB disease, bringing the U.S. closer to our goal of eliminating TB.” Read the full press release here.
CDC’s key messages about the USPSTF recommendation and various resources and other materials developed by the CDC’s Division of TB Elimination can be found on the CDC website and in the messages and resources summary.
The Huffington Post recently published a blog post written by Dr. Jono Mermin, director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, Tuberculosis and STD Prevention (NCHHSTP). In writing about the USPSTF recommendation, Dr. Mermin states, “Jump-starting progress toward TB elimination requires a dual approach. We must continue to respond to cases of TB disease and stop outbreaks when they occur. We must also expand efforts to find and treat latent TB infections before they can progress to TB disease.” Read the full post here.
California Tuberculosis Risk Assessment Tool (2016, California Department of Public Health and California TB Controllers Association)
Latent TB Infection Risk Assessment Tool (2016, Michigan Department of Health and Human Services)
Treatment for Latent Tuberculosis (TB) Infection: Isoniazid and Rifapentine (INH-RPT): Information for Patients (2016, Minnesota Department of Health TB Program, multiple languages)